Comment on 'Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'
- PMID: 18754887
- PMCID: PMC2715968
- DOI: 10.1111/j.1349-7006.2008.00864.x
Comment on 'Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'
Abstract
(Cancer Sci 2008; 99: 1706–1707)
Comment on
-
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.Cancer Sci. 2008 May;99(5):995-9. doi: 10.1111/j.1349-7006.2008.00780.x. Epub 2008 Feb 24. Cancer Sci. 2008. PMID: 18294285 Free PMC article.
References
-
- Jin Y, Desta Z, Ward B et al . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30–9. - PubMed
-
- Rothman KJ, Greenland S. Cohort studies. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008; 100–10.
-
- Glymour MM, Greenland S. Causal diagrams. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008; 183–212.
-
- Lash TL, Ahern TP, Cronin‐Fenton D et al . Modification of tamoxifen response: what have we learned? J Clin Oncol 2008; 26: 1764–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
